9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1

International Immunopharmacology

Volumn 20, Issue 1, 2014, Pages 213-220

  Kim, Ju Young ^a   Kim, Jung Young ^b   Cheon, Yoon Hee ^a   Kwak, Sung Chul ^a   Baek, Jong Min ^a   Kim, Youn Chul ^a   Yoon, Kwon Ha ^a   Oh, Jaemin ^a   Lee, Myeung Su ^a  

^a Wonkwang University   (South Korea)

^b Daejeon University   (South Korea)

Author keywords

9 Hydroxy 6,7 dimethoxydalbergiquinol; Osteoclasts; Osteoporosis; RANKL

Indexed keywords

9 HYDROXY 6,7 DIMETHOXYDALBERGIQUINOL; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; FLAVONOID; I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; UNCLASSIFIED DRUG; 9-HYDROXY-6,7-DIMETHOXYDALBERGIQUINOL; ACID PHOSPHATASE; ALLYL COMPOUND; ANISOLE DERIVATIVE; CELL SURFACE RECEPTOR; COLONY STIMULATING FACTOR 1; ISOENZYME; NFATC1 PROTEIN, MOUSE; OSCAR PROTEIN, MOUSE; TARTRATE-RESISTANT ACID PHOSPHATASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL STIMULATION; CONTROLLED STUDY; DALBERGIA; DALBERGIA ODORIFERA; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; OSTEOCLAST ASSOCIATED RECEPTOR GENE; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; TARTRATE RESISTANT ACID PHOSPHATASE GENE; ANIMAL; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; MACROPHAGE; METABOLISM; OSTEOCLAST;

ACID PHOSPHATASE; ALLYL COMPOUNDS; ANIMALS; ANISOLES; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; ISOENZYMES; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RECEPTORS, CELL SURFACE;

EID: 84896935512     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.03.001     Document Type: Article

References (32)

1. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 2003;18:599-609. (Pubitemid 36899309)
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42. (Pubitemid 40852708)
3. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005;208:30-49. (Pubitemid 41746383)
4. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999;190:1741-54. (Pubitemid 30013841)
5. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002;115:4317-25. (Pubitemid 35460702)
6. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 2001;20:1271-80. (Pubitemid 32233967)
7. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002;30:71-7. (Pubitemid 34044303)
8. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901. (Pubitemid 35460788)
9. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000;24:184-7. (Pubitemid 30094722)
10. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49. (Pubitemid 36917505)
11. Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992;360:741-5. (Pubitemid 23012271)
12. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994;266:443-8.
13. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004;279:26475-80. (Pubitemid 38798801)
14. Jia M, Nie Y, Cao DP, Xue YY, Wang JS, Zhao L, et al. Potential antiosteoporotic agents from plants: a comprehensive review. Evid Based Complement Alternat Med 2012;2012:364604.
15. An RB, Jeong GS, Kim YC. Flavonoids from the heartwood of Dalbergia odorifera and their protective effect on glutamate-induced oxidative injury in HT22 cells. Chem Pharm Bull (Tokyo) 2008;56:1722-4.
16. Lee SH, Kim JY, Seo GS, Kim YC, Sohn DH. Isoliquiritigenin, from Dalbergia odorifera, up-regulates anti-inflammatory heme oxygenase-1 expression in RAW264.7 macrophages. Inflamm Res 2009;58:257-62.
17. Goda Y, Katayama M, Ichikawa K, Shibuya M, Kiuchi F, Sankawa U. Inhibitors of prostaglandin biosynthesis from Dalbergia odorifera. Chem Pharm Bull (Tokyo) 1985;33:5606-9. (Pubitemid 16184055)
18. Sugiyama A, Zhu BM, Takahara A, Satoh Y, Hashimoto K. Cardiac effects of Salvia miltiorrhiza/Dalbergia odorifera mixture, an intravenously applicable Chinese medicine widely used for patients with ischemic heart disease in China. Circ J 2002;66:182-4. (Pubitemid 34464727)
19. Ha H, Lee JH, Kim HN, Kim HM, Kwak HB, Lee S, et al. alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J Immunol 2006;176:111-7. (Pubitemid 43023254)
20. Chuvpilo S, Jankevics E, Tyrsin D, Akimzhanov A, Moroz D, Jha MK, et al. Autoregulation of NFATc1/A expression facilitates effector T cells to escape fromrapid apoptosis. Immunity 2002;16:881-95. (Pubitemid 34786486)
21. Pan W, Mathews W, Donohue JM, Ramnaraine ML, Lynch C, Selski DJ, et al. Analysis of distinct tartrate-resistant acid phosphatase promoter regions in transgenic mice. J Biol Chem 2005;280:4888-93. (Pubitemid 40288663)
22. So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, et al. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem 2003;278:24209-16. (Pubitemid 36830257)
23. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ.Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57. (Pubitemid 30649812)
24. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006;24:33-63.
25. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003;305:211-4. (Pubitemid 36555454)
26. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40:251-64. (Pubitemid 46054562)
27. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999;4:1041-9. (Pubitemid 30054909)
28. Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, et al. Akt induces osteoclast differentiation through regulating the GSK3beta/NFATc1 signaling cascade. J Immunol 2012;188:163-9.
29. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65. (Pubitemid 36666005)
30. Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One 2007;2:e1058.
31. Sugatani T, Hruska KA. Akt1/Akt2 andmammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005;280:3583-9. (Pubitemid 40223824)
32. Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, et al. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 2006;116:528-35. (Pubitemid 43228371)